Foreign pharmaceutical firms are eyeing the world’s second largest market for profit opportunities as well as innovative assets.
The booth of pharmaceutical company Eli Lilly in a section for 'Public Health and Epidemic Prevention' at the 3rd China International Import Expo in Shanghai, November 6, 2020. Credit: Zhang Yuwei/Xinhua via Getty Images
While many foreign businesses are scaling back in China, U.S. pharmaceutical giant Eli Lilly is going against the grain with a string of new investments.
Eli Lilly officials pose during an expansion ceremony held at the company's site in Suzhou, October 11, 2024. Credit: Eli Lilly
The Indianapolis-based company is plowing $212 million to expand its plant in Suzhou, it announced on WeChat last month. The expansion, which will bring its total investment since 1996 in the southeastern city t
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Jeffrey Epstein aspired to do deals in China, corresponding with Peter Mandelson and David Stern, a German associate who was close to Andrew Mountbatten-Windsor. The Wire China reviews email trails from the Epstein files.
In an adaptation of her forthcoming book, The New Tech Titans of China, Rebecca Fannin profiles Shanghai-based Qiming Venture Partners and its American founder, Gary Rieschel.
Now on podcast platforms everywhere, The Wire China hits the airwaves to take you behind the scenes of the stories we cover each week. We are dedicated to understanding and explaining one of the biggest stories of our time: China’s economic rise and its influence on the world.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
